Following FDA approvals of monoclonal antibodies Leqembi and Kisunla for Alzheimer’s disease, dealmaking in the space has surged dramatically. GlobalData reports Alzheimer’s M&A deal values jumped 780%, rising from $2 billion in 2022 to $18 billion in 2024. Major players like AbbVie and Johnson & Johnson have pursued high-value acquisitions, including AbbVie’s $1.4 billion purchase of Aliada Therapeutics. Although sales remain modest and market penetration challenging, the approvals have renewed biotech interest in novel therapeutic targets and improved efficacy and safety profiles.